Platelet aggregation unchanged by lipoprotein-associated phospholipase A₂ inhibition: results from an in vitro study and two randomized phase I trials.
We explored the theorized upregulation of platelet-activating factor (PAF)- mediated biologic responses following lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibition using human platelet aggregation studies in an in vitro experiment and in 2 clinical trials.Full platelet aggregation concent...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3903475?pdf=render |
| _version_ | 1811319641304203264 |
|---|---|
| author | Bonnie C Shaddinger Yanmei Xu James H Roger Colin H Macphee Malcolm Handel Charlotte A Baidoo Mindy Magee John J Lepore Dennis L Sprecher |
| author_facet | Bonnie C Shaddinger Yanmei Xu James H Roger Colin H Macphee Malcolm Handel Charlotte A Baidoo Mindy Magee John J Lepore Dennis L Sprecher |
| author_sort | Bonnie C Shaddinger |
| collection | DOAJ |
| description | We explored the theorized upregulation of platelet-activating factor (PAF)- mediated biologic responses following lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibition using human platelet aggregation studies in an in vitro experiment and in 2 clinical trials.Full platelet aggregation concentration response curves were generated in vitro to several platelet agonists in human plasma samples pretreated with rilapladib (selective Lp-PLA2 inhibitor) or vehicle. This was followed by a randomized, double-blind crossover study in healthy adult men (n = 26) employing a single-agonist dose assay of platelet aggregation, after treatment of subjects with 250 mg oral rilapladib or placebo once daily for 14 days. This study was followed by a second randomized, double-blind parallel-group trial in healthy adult men (n = 58) also treated with 250 mg oral rilapladib or placebo once daily for 14 days using a full range of 10 collagen concentrations (0-10 µg/ml) for characterizing EC50 values for platelet aggregation for each subject. Both clinical studies were conducted at the GlaxoSmithKline Medicines Research Unit in the Prince of Wales Hospital, Sydney, Australia. EC50 values derived from multiple agonist concentrations were compared and no pro-aggregant signals were observed during exposure to rilapladib in any of these platelet studies, despite Lp-PLA2 inhibition exceeding 90%. An increase in collagen-mediated aggregation was observed 3 weeks post drug termination in the crossover study (15.4% vs baseline; 95% confidence interval [CI], 3.9-27.0), which was not observed during the treatment phase and was not observed in the parallel-group study employing a more robust EC50 examination.Lp-PLA2 inhibition does not enhance platelet aggregation.1) Study 1: ClinicalTrials.gov NCT01745458 2) Study 2: ClinicalTrials.gov NCT00387257. |
| first_indexed | 2024-04-13T12:46:23Z |
| format | Article |
| id | doaj.art-33d5118069104c88ade77010bd012e10 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-13T12:46:23Z |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-33d5118069104c88ade77010bd012e102022-12-22T02:46:22ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0191e8309410.1371/journal.pone.0083094Platelet aggregation unchanged by lipoprotein-associated phospholipase A₂ inhibition: results from an in vitro study and two randomized phase I trials.Bonnie C ShaddingerYanmei XuJames H RogerColin H MacpheeMalcolm HandelCharlotte A BaidooMindy MageeJohn J LeporeDennis L SprecherWe explored the theorized upregulation of platelet-activating factor (PAF)- mediated biologic responses following lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibition using human platelet aggregation studies in an in vitro experiment and in 2 clinical trials.Full platelet aggregation concentration response curves were generated in vitro to several platelet agonists in human plasma samples pretreated with rilapladib (selective Lp-PLA2 inhibitor) or vehicle. This was followed by a randomized, double-blind crossover study in healthy adult men (n = 26) employing a single-agonist dose assay of platelet aggregation, after treatment of subjects with 250 mg oral rilapladib or placebo once daily for 14 days. This study was followed by a second randomized, double-blind parallel-group trial in healthy adult men (n = 58) also treated with 250 mg oral rilapladib or placebo once daily for 14 days using a full range of 10 collagen concentrations (0-10 µg/ml) for characterizing EC50 values for platelet aggregation for each subject. Both clinical studies were conducted at the GlaxoSmithKline Medicines Research Unit in the Prince of Wales Hospital, Sydney, Australia. EC50 values derived from multiple agonist concentrations were compared and no pro-aggregant signals were observed during exposure to rilapladib in any of these platelet studies, despite Lp-PLA2 inhibition exceeding 90%. An increase in collagen-mediated aggregation was observed 3 weeks post drug termination in the crossover study (15.4% vs baseline; 95% confidence interval [CI], 3.9-27.0), which was not observed during the treatment phase and was not observed in the parallel-group study employing a more robust EC50 examination.Lp-PLA2 inhibition does not enhance platelet aggregation.1) Study 1: ClinicalTrials.gov NCT01745458 2) Study 2: ClinicalTrials.gov NCT00387257.http://europepmc.org/articles/PMC3903475?pdf=render |
| spellingShingle | Bonnie C Shaddinger Yanmei Xu James H Roger Colin H Macphee Malcolm Handel Charlotte A Baidoo Mindy Magee John J Lepore Dennis L Sprecher Platelet aggregation unchanged by lipoprotein-associated phospholipase A₂ inhibition: results from an in vitro study and two randomized phase I trials. PLoS ONE |
| title | Platelet aggregation unchanged by lipoprotein-associated phospholipase A₂ inhibition: results from an in vitro study and two randomized phase I trials. |
| title_full | Platelet aggregation unchanged by lipoprotein-associated phospholipase A₂ inhibition: results from an in vitro study and two randomized phase I trials. |
| title_fullStr | Platelet aggregation unchanged by lipoprotein-associated phospholipase A₂ inhibition: results from an in vitro study and two randomized phase I trials. |
| title_full_unstemmed | Platelet aggregation unchanged by lipoprotein-associated phospholipase A₂ inhibition: results from an in vitro study and two randomized phase I trials. |
| title_short | Platelet aggregation unchanged by lipoprotein-associated phospholipase A₂ inhibition: results from an in vitro study and two randomized phase I trials. |
| title_sort | platelet aggregation unchanged by lipoprotein associated phospholipase a₂ inhibition results from an in vitro study and two randomized phase i trials |
| url | http://europepmc.org/articles/PMC3903475?pdf=render |
| work_keys_str_mv | AT bonniecshaddinger plateletaggregationunchangedbylipoproteinassociatedphospholipasea2inhibitionresultsfromaninvitrostudyandtworandomizedphaseitrials AT yanmeixu plateletaggregationunchangedbylipoproteinassociatedphospholipasea2inhibitionresultsfromaninvitrostudyandtworandomizedphaseitrials AT jameshroger plateletaggregationunchangedbylipoproteinassociatedphospholipasea2inhibitionresultsfromaninvitrostudyandtworandomizedphaseitrials AT colinhmacphee plateletaggregationunchangedbylipoproteinassociatedphospholipasea2inhibitionresultsfromaninvitrostudyandtworandomizedphaseitrials AT malcolmhandel plateletaggregationunchangedbylipoproteinassociatedphospholipasea2inhibitionresultsfromaninvitrostudyandtworandomizedphaseitrials AT charlotteabaidoo plateletaggregationunchangedbylipoproteinassociatedphospholipasea2inhibitionresultsfromaninvitrostudyandtworandomizedphaseitrials AT mindymagee plateletaggregationunchangedbylipoproteinassociatedphospholipasea2inhibitionresultsfromaninvitrostudyandtworandomizedphaseitrials AT johnjlepore plateletaggregationunchangedbylipoproteinassociatedphospholipasea2inhibitionresultsfromaninvitrostudyandtworandomizedphaseitrials AT dennislsprecher plateletaggregationunchangedbylipoproteinassociatedphospholipasea2inhibitionresultsfromaninvitrostudyandtworandomizedphaseitrials |